Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE vs DUTASTERIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
FDA: Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate,FDA: Reduce risk of acute urinary retention,FDA: Reduce need for BPH-related surgery,Off-label: Male androgenetic alopecia
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
0.5 mg orally once daily.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Terminal half-life approximately 3-4 weeks (21-35 days) in young adults; 5-6 weeks in elderly; supports once-daily dosing due to slow elimination.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Extensively metabolized in liver via CYP3A4 and CYP1A2; minor metabolism by CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
Primarily fecal (70%) as metabolites; renal excretion accounts for <5% unchanged drug.
Approximately 50% bound to plasma proteins, primarily albumin.
>99% bound to albumin and alpha-1 acid glycoprotein; high affinity.
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
Approximately 300-500 L (3-5 L/kg), indicating extensive tissue distribution, particularly to prostate and seminal vesicles.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
Oral: Approximately 60% (range 40-80%) with food; not administered parenterally.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
No dose adjustment required for renal impairment (including dialysis).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
Contraindicated in Child-Pugh Class C; use with caution in mild to moderate impairment (Child-Pugh A/B) with no specific dose adjustment established.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Not indicated in pediatric patients; safety and efficacy not established.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
No specific dose adjustment required; monitor for adverse effects (e.g., dizziness, orthostatic hypotension) due to age-related comorbidities.
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
No FDA black box warning.
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Risk of high-grade prostate cancer in men aged 50-79 with elevated PSA and previous negative biopsy (see PLCO trial),Increased risk of sexual adverse events (impotence, decreased libido, ejaculation disorders) that may persist after discontinuation,Elevated PSA levels: use caution when interpreting PSA values; establish new baseline after 6 months of treatment
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
Women of childbearing potential (pregnancy category X; risk of fetal harm due to inhibition of 5α-reductase),History of hypersensitivity to dutasteride or other 5α-reductase inhibitors,Pediatric patients
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
No clinically significant food interactions. May be taken with or without food. Grapefruit juice does not affect dutasteride levels to a clinically relevant extent.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnormal development of external genitalia in male fetuses. Risk extends throughout all trimesters due to potential disruption of androgen-mediated development in male fetuses during the first trimester and cumulative effects from drug accumulation in adipose tissue. No adequate human studies exist; animal studies show teratogenicity in male offspring at clinically relevant doses.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
No data on dutasteride in human milk. M/P ratio unknown. Dutasteride is highly lipophilic and likely excreted in breast milk. Because of potential adverse effects on the nursing infant (e.g., interference with androgen-mediated development in male infants), breastfeeding is contraindicated during therapy and for at least 6 months after the last dose due to long half-life (approximately 5 weeks).
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
No dose adjustment studies in pregnancy because dutasteride is contraindicated. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) could affect dutasteride levels, but no adjustments are recommended as drug should not be used. If inadvertently used, discontinue immediately and monitor for adverse effects.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Monitor PSA levels cautiously, as dutasteride reduces serum PSA by approximately 50% after 6 months; double the PSA value for comparison to untreated men. Do not handle crushed or broken capsules if pregnant or planning pregnancy, as absorption through skin may cause fetal harm. Assess for signs of high-grade prostate cancer before initiating therapy, as dutasteride may increase the risk of Gleason 8-10 tumors. Onset of symptom relief may take 3-6 months; do not discontinue prematurely. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) as they increase dutasteride exposure.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Swallow the capsule whole; do not chew or open it.,It may take 3 to 6 months to see improvement in symptoms.,Avoid handling leaking or crushed capsules if you are a woman who is or may become pregnant; wash area immediately with soap and water if skin contact occurs.,Do not donate blood for at least 6 months after your last dose to prevent exposure to a pregnant woman.,Report any breast lumps, pain, or nipple discharge promptly.,You will need regular blood tests for PSA level monitoring; inform your doctor that you are taking dutasteride.,Dutasteride can decrease sperm count and may affect fertility; discuss this with your doctor if planning to father a child.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
"Dutasteride, a 5α-reductase inhibitor, may inhibit cytochrome P450 enzymes, particularly CYP3A4, which is involved in the metabolism of sulfisoxazole. This inhibition can lead to decreased clearance of sulfisoxazole, resulting in elevated plasma concentrations. Increased sulfisoxazole levels may potentiate its adverse effects, including hypersensitivity reactions, crystalluria, and hematologic toxicity such as agranulocytosis."
"Concomitant use of dutasteride, a 5α-reductase inhibitor, with nelfinavir, a protease inhibitor and potent CYP3A4 inhibitor, is predicted to increase the serum concentration of nelfinavir. This occurs because dutasteride may inhibit the metabolism of nelfinavir via competition for CYP3A4, leading to elevated nelfinavir levels and an increased risk of adverse effects such as gastrointestinal disturbances, hepatotoxicity, and metabolic complications. Clinical monitoring for toxicity and dose adjustments are warranted."
"Dutasteride, a 5α-reductase inhibitor, is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Itraconazole is a potent inhibitor of CYP3A4 and also inhibits P-glycoprotein. Coadministration leads to significantly increased serum concentrations of dutasteride, raising the risk of adverse effects such as gynecomastia, sexual dysfunction, and depression. The effect on itraconazole levels is minimal and clinically irrelevant."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE vs DUTASTERIDE, answered by our medical review team.
NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. DUTASTERIDE is a 5-alpha Reductase Inhibitor that works by Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE and DUTASTERIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. The standard adult dose of DUTASTERIDE is: 0.5 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE and DUTASTERIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. DUTASTERIDE is classified as Category D/X. Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnorm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.